CRESTOR

(Rosuvastatin)

Contents
Improving Lipid Management CRESTOR Efficacy Safety and Tolerability Clinical Pharmacology CRESTOR Dosing and Administration

GALAXY Programme

TM

Lipid Management

Lipid Management

Cholesterol management remains suboptimal

Insufficient doses Limited drug effectiveness Poor patient compliance

Options for improving lipid management

Dose titration Combination therapy More efficacious statin

Benefit of Lowering Cholesterol

Meta-analysis of 38 primary and secondary prevention trials, with more than 98,000 patients in total
0.0

Mortality (log odds ratio)

0.2

Total mortality, p=0.04

0.4

Mortality in CHD, p=0.012

0.6

0.8

1.0 0 4 8 12 16 20 24 28 32

Cholesterol reduction (%)

Adapted from Gould AL et al. Circulation 1998;97:946952

On-Treatment LDL-C is Closely Related to CHD Events in Statin Trials Lower is Better
30 4S - Placebo 25 Rx - Statin therapy PRA pravastatin ATV - atorvastatin

Secondary Prevention
4S - Rx

20

15

LIPID - Placebo CARE - Placebo LIPID - Rx CARE - Rx Primary Prevention HPS - Placebo HPS - Rx TNT ATV10 PROVE-IT - PRA WOSCOPS Placebo TNT ATV80 PROVE-IT ATV AFCAPS - Placebo AFCAPS - Rx ASCOT - Placebo ASCOT - Rx 40 (1.0) 60 (1.6) 80 (2.1) 100 (2.6) 120 (3.1) 140 (3.6) 160 (4.1) 180 (4.7) 200 (5.2) WOSCOPS - Rx
6

10

LDL-C achieved mg/dL (mmol/L)

Adapted from Rosensen RS. Exp Opin Emerg Drugs 2004;9(2):269-279 LaRosa JC et al. N Engl J Med 2005;352:1425-1435

Intensive LDL-C Lowering Improves Patient Outcomes

PROVE-IT
All-cause death or major cardiovascular events in all randomised subjects 30 pravastatin 40 mg Median LDL-C reduction 10% LDL-C achieved 95 mg/dL Event rate 26.3% 0.15 16% RR (p=0.005)

TNT
Major cardiovascular events in all randomised subjects atorvastatin 10 mg Mean LDL-C 101 mg/dL Event rate 10.9%

25
20 15 10 5 0 0

0.10 22% RRR (p<0.001) atorvastatin 80 mg Mean LDL-C 77 mg/dL Event rate 8.7% 1 2 3 Years 4 5

atorvastatin 80 mg Median LDL-C reduction 42% LDL-C achieved 62 mg/dL Event rate 22.4%

0.05

0 3 6 9 12 15 18 21 24 27 30 Months of follow-up

Cannon C et al. N Engl J Med 2004;350:1495-1504 LaRosa JC et al. N Engl J Med 2005;352:1425-1435

Relationship Between Changes in LDL-C and HDL-C Levels and CHD Risk

1% decrease in LDL-C reduces CHD risk by 1%

1% decrease in HDL-C increases CHD risk by 2-3%

Third Report of the NCEP Expert Panel. NIH Publication No. 01-3670 2001. http://hin.nhlbi.nih.gov/ncep_slds/menu.htm

Many Patients that are Treated are Still not Getting to Goal
2829 patients

1464 (52%) not at goal on starting dose 813 (55%) not titrated 651 (45%) titrated

1365 (48%) at goal on starting dose

448 (69%) not at goal

203 (31%) at goal

Patients with an LDL-C goal of <100mg/dL (CHD and/or diabetes mellitus) with HDL-C <45 mg/dL
Foley KA, Simpson RJ, Crouse JR et al. Am J Cardiol 2003;92:79-81

Even With Dose Titration, Many Patients Fail to Achieve LDL-C Goals
The ACCESS Study
80 Atorvastatin 1080 mg Simvastatin 1040 mg Lovastatin 2080 mg 60 Fluvastatin 2080 mg Pravastatin 1040 mg 40

20

At week 54, n=2543 CHD patients Ballantyne CM et al. Am J Cardiol 2001;88:265269

Evolution of Lipid Management Guidelines Driving the Need for More Effective Statin Therapy
European 1994 European 1998 European 2003

Lower LDL-C goals; wider target population; need for more effective therapies.

ATP I 1988

ATP II 1993

ATP III 2001

ATP III update 2004

Addressing The Unmet Medical Need in the Treatment of Dyslipidaemia

A need exists for more efficacious therapy to achieve: greater LDL-C reductions at low dose greater LDL-C reductions across the dose range more patients to guideline LDL-C goals improved HDL-C raising

CRESTOR

Efficacy

CRESTOR reduces LDL-C

by up to 63%
Rosuvastatin dose (mg) Placebo
0 n=13

5
n=17

10
n=17

20
n=17

40
n=18

Change in LDL-C from baseline (%)

10
20 30 40 50 60 70

45 *

52 *

55 *

63 *

*p<0.001 vs placebo Adapted from Olsson A. Cardiovasc Drug Rev 2002;20:303328

CRESTOR vs Comparators
The STELLAR Study
rosuvastatin 10 mg (n=158) rosuvastatin 20 mg (n=164) rosuvastatin 40 mg (n=158) atorvastatin 10 mg (n=158) atorvastatin 20 mg (n=156) atorvastatin 40 mg (n=160) atorvastatin 80 mg (n=167) simvastatin 10 mg (n=167) simvastatin 20 mg (n=164) simvastatin 40 mg (n=159) simvastatin 80 mg (n=165)

Patients (n=2288)

Hypercholesterolaemia
18 years

pravastatin 10 mg (n=162)
pravastatin 20 mg (n=166) pravastatin 40 mg (n=164)

1 Visit: Week: 6

2 2

3 1

4 0 Lipids Safety

5 4 Lipids Safety

6 6 Lipids Safety

Dietary run in / eligibility

Jones PH et al. Am J Cardiol 2003;92:152160

LDL-C Efficacy Across the Dose Range

The STELLAR Study

10
0

Dose, mg (log scale) 40 20

80 Rosuvastatin Atorvastatin Simvastatin Pravastatin

Change in LDL-C from baseline (%)

10 20 30 40 50 60 X X X X

n=485

X n=648

*
n=473

n=634

*p<0.002 vs atorvastatin 10 mg; simvastatin 10, 20, 40 mg; pravastatin 10, 20, 40 mg p<0.002 vs atorvastatin 20, 40 mg; simvastatin 20, 40, 80 mg; pravastatin 20, 40 mg p<0.002 vs atorvastatin 40 mg; simvastatin 40, 80 mg; pravastatin 40 mg
Adapted from Jones PH et al. Am J Cardiol 2003;92:152160

LDL-C efficacy at 10mg Dose

The STELLAR Study
Change in LDL-C from baseline (%)
0 5 10 15 20 25 30 35 40 45 50 55 60

10 mg * 10 mg 20 mg 40 mg

20 mg 80 mg

40 mg

Rosuvastatin Atorvastatin Simvastatin Pravastatin

10 mg

20 mg

40 mg

80 mg

10 mg

20 mg

40 mg

Rosuvastatin 10 mg (46%)

*p<0.002 vs atorvastatin 10 mg; simvastatin 10, 20, 40 mg; pravastatin 10, 20, 40 mg p<0.002 vs atorvastatin 20, 40 mg; simvastatin 20, 40, 80 mg; pravastatin 20, 40 mg p<0.002 vs atorvastatin 40 mg; simvastatin 40, 80 mg; pravastatin 40 mg
Adapted from Jones PH et al. Am J Cardiol 2003;92:152160

CRESTOR 5 mg provides greater LDL-C reductions than Atorvastatin 10 mg

12 weeks Pooled data - Blasetto 0
n=390 n=389 n=393

Change in LDL-C from baseline (%)

-10

-20

-30 -42% * -50 -47% * *p<0.001 vs. atorvastatin 10 mg

-36%

-40

-60

CRESTOR 5 mg CRESTOR 10 mg atorvastatin 10 mg

Blasetto JW et al. Am J Cardiol 2003;91(Suppl):3C10C.

Please consult local Prescribing Information for guidance on the use of CRESTOR

CRESTOR 10 mg versus Atorvastatin 10 mg Consistently Greater LDL-C Reductions

6 weeks
STELLAR Jones
n=158 n=158 n=156

8 weeks
MERCURY I Schuster
n=529
n=539 n=539

12 weeks Pooled data Davidson Schwartz

n=129 n=129

0
Change in LDL-C from baseline (%)
10 20 30

Olsson
n=132 n=132 n=139 n=139

Blasetto
n=389 n=389 n=393 n=393
36 47

n=128 n=128

37

37

35

n=127 n=127
35

n=127 n=127

40
46 47

39

43

50 60

47

50

*p<0.001 vs atorvastatin
Jones PH et al. Am J Cardiol 2003;92:152160 Schuster H et al. Am Heart J 2004; 147: 705-712 Davidson M et al. Am J Cardiol 2002;89:26875 Schwartz G et al. Am Heart J 2004: 148:e4:H1-H9 Olsson AG et al. Am Heart J 2002;144:104451 Blasetto JW et al. Am J Cardiol 2003;91(Suppl):3C10C

Rosuvastatin 10 mg Atorvastatin 10 mg

CRESTOR 10 mg versus Atorvastatin 20 mg Provides Greater LDL-C Reductions

6 weeks STELLAR Jones
n=156 n=155

8 weeks PULSAR Clearfield

n=493 n=481

0 -10 -20 -30

RADAR Jukema
n=230 n=231

CORALL Wolffenbuttel
n=131 n=132

MERCURY I Schuster
n=539 n=925

Change in LDL-C from baseline (%)

-38%

-40 -50 -60

-46% ns

-43%

-44% *

-41% -46% -45%

-43% -47%

-44%

** CRESTOR 10 mg atorvastatin 20 mg

*p<0.05, **p<0.001 vs. atorvastatin 20 mg

Jones PH et al. Am J Cardiol 2003;92:152160. Jukema J et al. Curr Med Res 2005 in press Wolffenbuttel et al. Journal of Internal Medicine 2005; 257: 531-539 Clearfield M et al. Atherosclerosis Supplements 2005;6(1)104 Abs W16-P-014 Schuster H et al. Am Heart J 2004;147:705712.

CRESTOR 40 mg versus Atorvastatin 80 mg Provides Greater LDL-C Reductions

0 6 weeks STELLAR Jones
n=157 n=165

8 weeks POLARIS Leiter

n=428 n=432

18 weeks RADAR CORALL Jukema Wolffenbuttel

n=230 n=231 n=130 n=132

Change in LDL-C from baseline (%)

-10

-20

-30

-40 -51 -55 ns -56 ** -52 -55 *** -48 -54 * Rosuvastatin 40 mg Atorvastatin 80 mg -48

-50

-60

*p<0.01, **p<0.001, ***p<0.0001 vs atorvastatin 80 mg;

Jones PH et al. Am J Cardiol 2003;92:152160. Leiter LA et al. Atherosclerosis Supplements 2005; 6 (1) 113 Abs W16-P-051 Wolffenbuttel et al. Journal of Internal Medicine 2005; 257: 531-539 Jukema J et al. Curr Med Res 2005 in press

CRESTOR versus other statins Achievement of LDL-C Goals Across Dose Range
Patients achieving 2003 European LDL-C goals
100
87% # 83%

Patients achieving 2003 European LDL-C goals (%)

80
* 69% 72%

75% 66%

Rosuvastatin Atorvastatin Simvastatin Pravastatin

60

58% 48% 44%

40

36%

20

20% 12% 3%

22%

n=156 n=160 n=157

10mg 20mg 40mg

n=158 n=155 n=156n=165

10mg 20mg 40mg 80mg

n=165 n=162 n=158 n=163

10mg 20mg 40mg 80mg

n=160 n=164n=161 10mg 20mg 40mg

LDL-C <3mmol/l (115mg/dl) in general; <2.5mmol/l (97mg/dl) for patients with clinically established CVD or type 2 diabetes *p<0.002 vs atorvastatin 10 mg; simvastatin 10, 20, 40 mg; pravastatin 10, 20, 40 mg p<0.002 vs atorvastatin 20 mg; simvastatin 20, 40 mg; pravastatin 20, 40 mg #p<0.002 vs atorvastatin 40 mg; simvastatin 40, 80 mg; pravastatin 40 mg Kritharides L. Eur Heart J Suppl 2004;6(Suppl A):A12-A18

CRESTOR versus other statins Achievement of LDL-C Goals Across Dose Range
Patients achieving NCEP ATP III LDL-C goals#
100
89% 89% 85% 75% 69% 63% 66% 55% 51% 44% 82% 82%

Patients achieving their NCEP ATP III LDL-C goals (%)

80

* 82%

Rosuvastatin Atorvastatin Simvastatin Pravastatin

60

40
31%

20

n=156 n=160 n=157 10mg 20mg 40mg

n=158 n=155 n=156 n=165 10mg 20mg 40mg 80mg

n=165 n=162 n=158 n=163 10mg 20mg 40mg 80mg

n=160 n=164 n=161 10mg 20mg 40mg

#LDL-C

goal <100mg/dl for high-risk; <130 for medium risk & <160 for low-risk patients

*p<0.002 vs. simvastatin 10 mg and 20 mg; pravastatin 10 mg, 20 mg and 40 mg p<0.002 vs. atorvastatin 20 mg, simvastatin 20mg and 40 mg; pravastatin 20 mg and 40 mg p<0.002 vs. simvastatin 40 mg and pravastatin 40 mg

Jones PH et al. Am J Cardiol 2003;92:152160

CRESTOR versus Atorvastatin Change in HDL-C

The STELLAR Study

12

Change in HDL-C from baseline (%)

* 10 8 6 4 2 0 ns

n=473

Rosuvastatin Atorvastatin

n=634

10

20

40

80

Dose (mg); log scale

*p<0.002 vs atorvastatin 20, 40 and 80 mg p<0.002 vs atorvastatin 40 and 80 mg
Adapted from Jones PH et al. Am J Cardiol 2003;92:152160

CRESTOR versus other statins Change in HDL-C

The STELLAR Study
12

Change in HDL-C from baseline (%)

10 8 6 4 * 7.7

9.6 9.5

Rosuvastatin Atorvastatin Simvastatin Pravastatin

6.8 5.7 4.8 4.4 3.2 2.1 6.0 5.3 5.2 4.4

5.6

10 20 40

10 20 40 80

10 20 40 80

10 20 40

Dose (mg)
*p<0.002 vs pravastatin 10 mg p<0.002 vs atorvastatin 20, 40, 80 mg; simvastatin 40 mg; pravastatin 20, 40 mg p<0.002 vs atorvastatin 40, 80 mg; simvastatin 40 mg; pravastatin 40 mg Observed data in ITT population
Adapted from Jones PH et al. Am J Cardiol 2003;92:152160

CRESTOR versus other statins Change in Triglycerides

The STELLAR Study
Dose (mg)
0 5 10 20 40 10 20 40 80 10 20 40 80 10 20 40

Change in TG from baseline (%)

10 15 20 25 30
12 15 18 20 18

13

20
24 23 26

27
28

Rosuvastatin Atorvastatin Simvastatin Pravastatin

*p<0.002 vs pravastatin 10, 20 mg p<0.002 vs simvastatin 40 mg; pravastatin 20, 40 mg p<0.002 vs simvastatin 40 mg; pravastatin 40 mg Adapted from Jones PH et al. Am J Cardiol 2003;92:152160

CRESTOR Efficacy Summary

Rosuvastatin is the more effective statin at lowering LDL-C10-21

highly effective reductions in LDL-C of up to 63%

greater LDL-C lowering versus atorvastatin Rosuvastatin 10 mg can reduce LDL-C by approximately 50% and produces: greater reductions in LDL-C than the same and some higher doses of other statins11-18 greater reductions in LDL-C than atorvastatin 10 and 20 mg 13,17,18,19. greater achievement of LDL-C goals than commonly prescribed doses of other statins, avoiding the need to titrate to higher doses11,17,19,21,25. Rosuvastatin produces a significant increase in HDL-C which is maintained across the dose range11

Safety Profile

CRESTOR

Overall safety & adverse event profile as determined by controlled clinical trials
The Rosuvastatin Clinical Development Programme (n=12,400) included a wide range of patients treated with rosuvastatin 5-40 mg, including many at increased cardiovascular risk, reflecting those seen in general medical practice: Male; 6,530 (53%), Female; 5,870 (47%) Mean age 58 years, No upper age limit; 3,894 (31%) 65 years Diabetes mellitus; 2,073 (17%) Hypertension; 6,472 (52%) Coronary heart disease; 4,487 (36%) Renal impairment: Mild; 5,513 (44%) Moderate; 975 (8%) Severe; 39 (0.3%)

Shepherd J et al. Am J Cardiol 2004;94:882-888

CRESTOR overall safety & adverse event profile

Rosuvastatin is generally well tolerated with an adverse event profile similar to currently marketed statins Most common related adverse events - myalgia, asthenia, abdominal pain, nausea (mild and transient) Well tolerated regardless of age, sex, ethnicity, presence of co-morbidities or concomitant medications

Similar number of adverse events leading to withdrawal as other currently marketed statins

Shepherd J et al. Am J Cardiol 2004;94:882-888

CRESTOR overall safety & adverse event profile

Percentage of patients with an adverse event leading to withdrawal
8 7 6 5

4
3 2

3.2%

3.2% 2.5% 2.5%

1040 mg 1080 mg

1
0

540 mg

1080 mg

rosuvastatin
(n=3912)

atorvastatin
(n=2899)

simvastatin
(n=1457)

pravastatin
(n=1278)

Shepherd J et al. Am J Cardiol 2004;94:882-888

CRESTOR Safety Summary

Tolerability profile has been well-researched in a large number of patients representing real population Overall tolerability profile of rosuvastatin is similar to that seen with currently marketed statins
well tolerated with a low rate of withdrawals due to adverse events adverse events usually mild and transient

rhabdomyolysis is very rare with rosuvastatin (<0.01%) which is in line with that reported for other currently marketed statins
renal function was maintained or tended to improve slightly with long-term treatment

Favourable benefitrisk profile

Clinical Pharmacology of CRESTOR

Pharmacokinetic Profile of Selected Statins

Rosuvastatin
CYP450 3A4 metabolism Clinically significant metabolites Plasma clearance Relatively hydrophilic Bioavailability (%) Elimination half-life (hours) No No Dual renal / hepatic Yes 20 20

Atorvastatin
Yes Yes Primarily hepatic No 12 11-14

Simvastatin
Yes Yes Dual renal / hepatic No <5 3

Pravastatin
No No Dual renal / hepatic Yes 18 2

CRESTOR Dosing and Administration

CRESTOR - Dosing and Administration

Dose range 540 mg Usual start dose 5mg or 10mg

Dependent on level of lipid lowering required

Maximum LDL-C response within 4 weeks

significant response within 2 weeks

Once daily, any time of day, with or without food

Please refer to local Prescribing Information

GALAXY ProgrammeTM
The GALAXY ProgrammeTM is a large, comprehensive, long-term and evolving global research initiative sponsored by AstraZeneca investigating cardiovascular risk reduction and patient outcomes with rosuvastatin It has been designed to build on current thinking to address important unanswered questions in statin research Includes studies investigating the effects of rosuvastatin on: atherogenic lipid profile and inflammatory markers atherosclerosis outcomes Will provide additional short- and long-term efficacy and safety data for rosuvastatin

Designed to evaluate whether these effects translate into beneficial effects on atherosclerosis and significant reductions in cardiovascular events.
Schuster H & Fox J. Exp Opin Pharmacother 2004;5:1187-1200

CRESTOR - Overall Summary

CRESTOR produces beneficial effects on key lipid parameters across the dose range
the more effective statin at lowering LDL-C with greater LDL-C lowering versus atorvastatin in more than 17 comparative studies involving >16,000 patients rosuvastatin 10 mg can reduce LDL-C by approximately 50% and has been shown to reduce LDL-C more than atorvastatin 10 mg and 20 mg rosuvastatin 10 mg gets more patients to their LDL-C goal than commonly prescribed doses of other currently marketed statins, avoiding the need to titrate to higher doses significant increase in HDL-C which is maintained across the dose range

Tolerability and safety profile similar to other currently marketed statins

Low potential for significant drugdrug interactions

Has a comprehensive clinical development programme

References
Schuster H. Improving lipid management to titrate, combine or switch. Int J Clin Pract, July 2004, 58, 7, 689-694 Gould AL, Rossouw JE, Santanello NC et al. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998;97:946952. Rosensen RS. Statins: can the new generation make an impression? Exp Opin Emerg Drugs 2004;9(2):269-279. LaRosa J, Grundy S, Waters D, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-1435. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomised placebocontrolled trial. Lancet 2002;360:722. Cannon C, Braunwald E, McCabe C et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med 2004;350 (15):1495-1504 Third Report of the NCEP Expert Panel. NIH Publication No. 01-3670 2001. http://hin.nhlbi.nih.gov/ncep_slds/menu.htm Foley KA, Simpson RJ, Crouse JR et al. Effectiveness of Statin Titration on Low-Density Lipoprotein Cholesterol Goal Attainment in Patients at High Risk of Atherogenic Events. Am J Cardiol 2003;92:79-81 Ballantyne CM, Andrews TC, Hsia JA et al. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol 2001;88:265269 Olsson A, McTaggart F, Raza A. Rosuvastatin A highly effective new HMG-Co A reductase inhibitor. Cardiovasc Drug Rev 2002;20:303328 Jones PH, Davidson MH, Stein EA et al for the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial) Am J Cardiol 2003;92:152160 Blasetto JW, Stein EA, Brown WV et al. Efficacy of Rosuvastatin Compared with Other Statins as Selected Starting Doses in Hypercholesterolemic Patients and in Special Population Groups. Am J Cardiol 2003;91(Suppl):3C10C. Schuster H, Barter PJ, Stender S et al. Effect of switching to rosuvastatin from atorvastatin or other statins on achievement of international low-density lipoprotein cholesterol goals: MERCURY I trial. Am Heart J 2004;147:705-712 Davidson M, Ma P, Stein EA et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002;89:268275 Schwartz GG, Bolognese MA, Tremblay BP et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. Am Heart J 2004:148:e4:H1-H9

Olsson AG, Istad H, Luurila O et al. Effect of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002;144:10441051
Jukema J, Liem AH, Dunselman PHJM et al. LDL/HDL-C ratio in patients with cardiovascular disease and low HDL-C: results of the the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. Current Medical Research 2005 in press. Wolffenbuttel B et al. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes CORALL study. J Int Med 2005;257:531-539 Clearfield M, Amerena J, Bassand JP et al. Efficacy and safety of rosuvastatin 10mg versus atorvastatin 20mg: results of the PULSAR study. Atherosclerosis Supplements 2005;6(1)104 Abs W16-P-014. Leiter LA, Rosenson RS, Stein E et al. Rosuvastatin 40mg versus atorvastatin 80mg in high-risk patients with hypercholesterolaemia: early results results of the POLARIS study. Atherosclerosis Supplements 2005;6(1):113 Abs W16-P-051. Kritharides L. Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals. Eur Heart J Suppl 2004;6(Suppl A): A12-A18.

Shepherd J, Hunninghake DB, Stein EA et al. Safety of rosuvastatin. Am J Cardiol 2004;94:882-888

White, CM. A Review of the Pharmacologic and Pharmacokinetic Aspects of Rosuvastatin. J Clin Pharm, 2002;42:963-970 McTaggart F, Buckett L, Davidson R et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3- hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001;87(Suppl):28B32B Schuster H, Fox J, Investigating cardiovascular risk reduction the Rosuvastatin GALAXY Programme. Exp Opin Pharmacother 2004;5(5):1187-1200